Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAK Latar Belakang: Perlunya stratifikasi risiko dan evaluasi terapi berkala pada sindrom koroner akut (SKA) terkait mortalitas dan morbiditas di kemudian hari.Petanda biokimia ST2 praktis dan lebih murah, serta tidak dipengaruhi oleh usia,jenis kelamin dan fungsi ginjal. Kadarnya dapat berbeda antar ras, namun belumada data yang menyajikan profil kadar ST2 awal dan penurunan pasca terapidefinitif di Indonesia. Metode: Studi deskriptif longitudinal pada 40 subjek yang diperiksan kadar ST2secara ELISA saat awal dan setelah terapi definitif. Hasil: Didapatkan proporsi kadar ST2 awal <35 ng/mL lebih dominan ( 52,5% vs.47,5%). Kadar ST2 awal tertinggi didapatkan pada IMA-NST, yaitu 46,79 ng/mL(kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) yang memiliki awitan terlama(48 jam). Hipertensi memiliki proporsi tertinggi (91,7%) dan usia berbanding lurusdengan kadar ST2. Proporsi kadar ST2 yang tidak mengalami penurunan sebesar30%, terutama APTS (41,7%) dengan usia rerata 3 tahun lebih tua (58 tahun vs. 55tahun).Simpulan: Didapatkan kadar ST2 <35 ng/mL pada sebagian besar subjek, tertinggipada IMA-NST. Lama awitan, hipertensi dan usia diduga berhubungan dengankadar ST2 awal tinggi. Kadar ST2 pasca terapi menurun pada sebagian besar subjek.ABSTRACT Background: Acute coronary syndrome been a burden for causing high mortality and morbidity, therefore risk stratification and therapy evaluation are needed. Anew biomarker ST2 is practice and less expensive for daily usage and it also doesn?tinfluenced by age, gender, and kidney function. The ST2 value are different in dueto race among countires. There is no data available regarding ST2 baseline and afterdefinitive treatment profile in Indonesia.Method: It is a longitudinal descriptive study that conducted prospectively on 40subjects. The value of ST2 was examined using ELISA methods at baseline andafter definite treatment. Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs. 47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had thelongest onset of chest pain (48 hours). Hypertension had the highest proporsion(91,7%) and age were proportional to the ST2 value. The proportion of the ST2value that didn?t decreased after therapy were lesser than the decrease (30% vs.70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 yearsold).Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higherthan ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 levelwere found in NSTEMI-ACS. Onset of angina, hypertension and age were foundto be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment. ;Background: Acute coronary syndrome been a burden for causing high mortality and morbidity, therefore risk stratification and therapy evaluation are needed. Anew biomarker ST2 is practice and less expensive for daily usage and it also doesn?tinfluenced by age, gender, and kidney function. The ST2 value are different in dueto race among countires. There is no data available regarding ST2 baseline and afterdefinitive treatment profile in Indonesia.Method: It is a longitudinal descriptive study that conducted prospectively on 40subjects. The value of ST2 was examined using ELISA methods at baseline andafter definite treatment. Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs. 47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had thelongest onset of chest pain (48 hours). Hypertension had the highest proporsion(91,7%) and age were proportional to the ST2 value. The proportion of the ST2value that didn?t decreased after therapy were lesser than the decrease (30% vs.70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 yearsold).Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higherthan ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 levelwere found in NSTEMI-ACS. Onset of angina, hypertension and age were foundto be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment. ;Background: Acute coronary syndrome been a burden for causing high mortality and morbidity, therefore risk stratification and therapy evaluation are needed. Anew biomarker ST2 is practice and less expensive for daily usage and it also doesn?tinfluenced by age, gender, and kidney function. The ST2 value are different in dueto race among countires. There is no data available regarding ST2 baseline and afterdefinitive treatment profile in Indonesia.Method: It is a longitudinal descriptive study that conducted prospectively on 40subjects. The value of ST2 was examined using ELISA methods at baseline andafter definite treatment. Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs. 47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had thelongest onset of chest pain (48 hours). Hypertension had the highest proporsion(91,7%) and age were proportional to the ST2 value. The proportion of the ST2value that didn?t decreased after therapy were lesser than the decrease (30% vs.70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 yearsold).Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higherthan ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 levelwere found in NSTEMI-ACS. Onset of angina, hypertension and age were foundto be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment. ;Background: Acute coronary syndrome been a burden for causing high mortality and morbidity, therefore risk stratification and therapy evaluation are needed. Anew biomarker ST2 is practice and less expensive for daily usage and it also doesn?tinfluenced by age, gender, and kidney function. The ST2 value are different in dueto race among countires. There is no data available regarding ST2 baseline and afterdefinitive treatment profile in Indonesia.Method: It is a longitudinal descriptive study that conducted prospectively on 40subjects. The value of ST2 was examined using ELISA methods at baseline andafter definite treatment. Result: The proporsion of baseline ST2 <35 ng/mL are dominan (52,5% vs. 47,5%). The highest of ST2 baseline value are found in NSTEMI-ACS it?s 46,79ng/mL (kuartil-1 3,67 ng/mL, dan kuartil-3 102,41 ng/mL) and it also had thelongest onset of chest pain (48 hours). Hypertension had the highest proporsion(91,7%) and age were proportional to the ST2 value. The proportion of the ST2value that didn?t decreased after therapy were lesser than the decrease (30% vs.70%), especially UAP (41,7%) that had 3 years older ages (58 years old vs. 55 yearsold).Conclusion: Proportion of baseline of ST2 value <35 ng/mL groups were higherthan ST2 level ≥35 ng/mL (52,5% vs. 47,5%), and the highest baseline ST2 levelwere found in NSTEMI-ACS. Onset of angina, hypertension and age were foundto be dominant in patient with early ST2 level ≥35 ng/mL. The ST2 value were decreasing in most of the subject after treatment. "

"ABSTRAKNama : Tanti Oktikasari Program Studi : Pendidikan Dokter Spesialis Patologi Klinik Judul : Peran kadar ST2 dalam model prognostik untuk risiko terjadinya major adverse cardiac events jangka pendek pada pasien gagal jantung akut Pendahuluan: Gagal jantung akut merupakan salah satu penyebab tingginya angka kematian dan perawatan kembali penderita dengan gagal jantung kronik. Jumlah kematian akibat gagal jantung mencapai 60.000 kasus per tahun. Pasien usia >65 tahun merupakan penyebab paling sering terjadinya perawatan akibat gagal jantung akut di rumah sakit. Soluble ST2 ST2 merupakan reseptor yang termasuk ke dalam keluarga interleukin-1 yang digunakan sebagai penanda peregangan, remodelling, dan fibrosis miokardium sehingga dapat digunakan sebagai penanda prognostik terjadinya major adverse cardiac events MACE pada pasien gagal jantung akut. Metode: Desain penelitian kohort prosfektif terhadap 77 subyek dengan gagal jantung akut, dilakukan pemeriksaan kadar ST2 saat masuk rumah sakit dan ditetapkan beberapa faktor risiko klinis dan laboratoris berupa jenis kelamin laki-laki, kelompok usia >65 tahun, riwayat diabetes melitus, kadar ureum darah, dan kebiasaan merokok. Luaran klinis berupa MACE dan kematian pasien gagal jantung akut dilakukan observasi selama 30 hari. Hasil: Tidak terdapat hubungan antara kadar ST2 >35 ng/mL dengan terjadinya MACE jangka pendek pada penderita gagal jantung akut di RSUPN-CM. Faktor risiko gagal jantung akut yang berhubungan dengan terjadinya MACE adalah riwayat penyakit jantung koroner dan kadar NT-proBNP >1000 pg/mL. Peran kadar ST2 >35 ng/mL tidak dapat digunakan dalam model prognostik jangka pendek pada pasien gagal jantung akut. Nilai cut off kadar ST2 untuk terjadinya kematian selama 30 hari adalah 49,4 ng/mL. Tidak terdapat hubungan kadar ST2 setelah digabungkan dengan kadar NT-proBNP dengan terjadinya MACE jangka pendek pada pasien gagal jantung akut. Kesimpulan: Kadar ST2 >35 ng/mL tidak dapat digunakan dalam model prognostik jangka pendek pada pasien gagal jantung akut.

---

ABSTRACTName Tanti Oktikasari Study Program Clinical Pathology Residency Program Title The role of ST2 levels in the model prognosis for the short term risk of major adverse cardiac events in patients with acute heart failure Introduction. Acute heart failure is the most frequent cause of hospitalization and mortality in patients with chronic heart failure. The number of death in patients heart failure reached 60000 cases per year. Patients with age 65 years are the most frequent cause of hospitalization due to acute heart failure. Soluble ST2 ST2 is a member of interleukin 1 receptor family that used as a biomarker of myocardial stretch, remodelling, and fibrosis. This parameter is used as a prognostic marker for the occurrence of major adverse cardiac events in patients with acute heart failure. Methods. Prospective cohort study design. Subjects consisted of 77 patients with acute heart failure and examine the levels of ST2 at the time of admission, the next set of clinical risk factors and laboratory consisting of a type of male sex, age group 65 years, history of diabetes melitus, blood ureum 92 mg dL, and current smoking. The clinical outcomes such as MACE and mortality of patients with acute heart failure following within 30 days. Results. Prognostic models obtained is acute heart failure patients with a history of coronary heart disease and levels of NT proBNP is 1000 pg mL. Levels of ST2 35 ng mL can not be used to assess the prognosis for the occurrence of MACE during 30 days hospitalization. The cut off point of ST2 levels for the mortality was 49.4 ng mL. There is no substantial improvement in addition of ST2 to clinical model with NT proBNP. Conclusion. Levels of ST2 35 ng mL can not be used to assess the prognosis for the occurrence of MACE during 30 days hospitalization."

"Latar Belakang: Pada pasien dengan penyakit jantung, gangguan pada fungsi paru dapat memperburuk kondisi jantung dengan menyebabkan terjadinya dekompensasi. Infeksi virus SARS-CoV-2 berpotensi mengakibatkan terjadinya fibrosis paru dan gangguan fungsi paru lainnya yang dapat dinilai dengan pemeriksaan spirometri dan kadar ST2 terlarut dalam darah. Infeksi COVID-19 varian Omicron mengakibatkan luaran yang relatif lebih baik dibandingkan varian Delta namun jumlah kasusnya lebih banyak dan tetap dapat mengakibatkan komplikasi tersebut. Oleh sebab itu, penelitian ini akan membandingkan kedua parameter tersebut pada pasien pasca infeksi COVID-19 varian Omicron dan Delta.Tujuan: Mengetahui hubungan kadar ST2 terlarut dan luaran spirometri pada pasien pasca COVID-19 varian Omicron dibandingkan varian Delta pada pasien dengan penyakit kardiovaskular serta perbedaan pada kedua populasi.Metode: Studi observasional potong lintang pada 76 pasien dengan penyakit jantung yang terinfeksi COVID-19 varian Omicron dan Delta dilakukan pemeriksaan spirometri dan kadar ST terlarut 12 minggu pasca konfirmasi negatif. Analisis statistik dilakukan untuk mengetahui hubungan antara kadar ST2 terlarut pada varian Omicron dibandingkan dengan Delta terhadap gangguan fungsi paru menggunakan spirometri dan perbedaan luaran kedua varian.Hasil: Dari 76 subjek penelitian, proporsi pasien dengan varian Omicron lebih banyak dibandingkan Delta (53 orang berbanding 23 orang), dengan perbedaan pada proporsi pasien dengan gagal jantung, penyakit jantung koroner, penerima vaksin dan distres pernafasan akut pada admisi. Kadar ST2 terlarut (p=0.026, OR 1.01 (95% CI 1.00-1.01)) dan kondisi gagal jantung (p=0.019, OR 6.07 (95% CI 1.34-27.47)) memiliki hubungan terhadap kejadian luaran gambaran spirometri abnormal khususnya gambaran restriksi terutama pada varian Omicron, namun hubungan ini lemah dan kemaknaan klinis tidak signifikan.Hasil studi ini mengindikasikan bahwa kadar ST2 terlarut, meskipun lemah, mungkin memiliki asosiasi terhadap kelainan spirometri pada penyintas COVID-19, namun temuan ini terbatasi oleh perbedaan pada masing-masing populasi dari studi ini.

---

Background: In patients with heart disease, impaired lung function can exacerbate cardiac conditions due to decompensation. Infection by the SARS-CoV-2 virus has the potential to cause pulmonary fibrosis and other lung impairment which could be assessed by spirometry and measurement of soluble ST2 levels. Omicron infection resulted in a relatively better outcome than the Delta variant but higher number of cases and it could still cause these complications. Therefore, this study aims to compare these two parameters in survivors of COVID-19 infected by Omicron and Delta variant.

Objective: To determine the relationship between soluble ST2 levels and spirometry outcomes in patients with cardiovascular disease after COVID-19 infection by Omicron variant as compared to the Delta variant and the differences in the two populations.

Methods: A cross-sectional observational study on 76 patients with heart disease who were infected by Omicron and Delta variant of COVID-19 underwent spirometry and blood sampling for soluble ST levels at the Outpatient clinic in 12 weeks after confirmed negative. Statistical analysis will be performed to find out the association between soluble ST2 levels in the Omicron variant compared to Delta and impairment of lung function using spirometry and the difference in the outcomes of the two variants.

 

Results: From 76 study subjects, the proportion of survivor of Omicron variant was higher than Delta (53 versus 23), with differences in the proportion of patients with heart failure, coronary artery disease, recipients of vaccine and acute respiratory distress syndrome on admission. Soluble ST2 levels (p=0.026, OR 1.01 (95% CI 1.00-1.01)) and heart failure (p=0.019, OR 6.07 (95% CI 1.34-27.47)) have a significant association to abnormal spirometry pattern, especially the restrictive pattern in the Omicron variant, however this relationship may be weak and the clinical implication might be insignificant.

Conclusion: The results of this study indicate that soluble ST2 levels, although weak, may have an association with spirometry abnormalities in COVID-19 survivors, but these findings may be limited by differences in each population and study design."

"Latar Belakang : Infeksi COVID-19 telah diketahui masih dapat menyebabkan gejala sampai 90 hari dan bahkan lebih, meski infeksi akutnya telah berlalu. Hal ini disebabkan karena adanya fenomena sindroma pasca COVID-19. Mekanisme kejadian tersebut sampai saat ini masih belum diketahui pasti. Hal tersebut diduga kuat akibat adanya fibrosis di beberapa organ, terutama jantung dan paru. Sementara itu, beberapa studi telah menyebutkan bahwa sST2 merupakan penanda fibrosis jantung. Meskipun demikian, sampai saat ini belum ada penelitian yang mencoba mengetahui faktor-faktor apa saja yang memiliki hubungan dengan kejadian fibrosis pasca infeksi COVID-19. Kadar sST2 pada pasien komorbid kardiovaskular tanpa COVID-19 dan populasi orang sehat, khususnya di Indonesia juga belum diketahui.Tujuan : Mengetahui perbandingan kadar sST2 pada pasien komorbid kardiovaskular 12 minggu pasca infeksi COVID-19 dengan pasien komorbid kardiovaskular tanpa COVID-19 dan populasi orang sehat, serta hubungannya dengan faktor-faktor admisi.Metode : Penelitian ini merupakan studi observasional potong lintang. Kadar sST2 pada pasien 12 minggu pasca infeksi COVID-19 dibandingkan dengan komorbid kardiovaskular akan dibandingkan dengan kelompok kontrol, yaitu kontrol 1 yang merupakan pasien komorbid kardiovaskular tanpa COVID-19 dan kontrol 2 yang merupakan populasi orang sehat. Kelompok kontrol dipilih menggunakan metode matching. Hubungan faktor klinis dan laboratoris saat dengan kadar sST2 pada pasien 12 minggu pasca infeksi COVID-19 dianalisis menggunakan analisis multivariat.Hasil : Terdapat 162 subjek yang menyelesaikan rangkaian penelitian yang terdiri atas 100 subjek dengan penyintas COVID-19 disertai komorbiditas kardiovaskular (kelompok kasus), 31 subjek dengan komorbiditas kardiovaskular tanpa COVID-19 (kelompok kontrol 1), dan 31 subjek sehat tanpa riwayat COVID-19 dan komorbiditas kardiovaskular (kelompok kontrol 2). Ketiga kelompok memiliki karakteristik yang sama. Terdapat perbedaan signifikan rerata nilai sST2 antara kelompok kasus dibandingkan kontrol 1 dan kontrol 2 (2786 ± 73 vs 2666 ± 162 pg/l, p <0.001 dan 2786 ± 73 vs 2517.15 ± 321 pg/l, p < 0.001), serta kontrol 1 dibandingkan kontrol 2 (2666 ± 162 pg/l vs 2517.15 ± 321 pg/l, p < 0.001). Analisis multivariat menunjukkan PaO2 (p < 0.001) dan nilai CT (p = 0.04) memiliki hubungan dengan kadar sST2 pada pasien 12 minggu pasca infeksi COVID-19.Kesimpulan : Terdapat perbedaan signifikan antara kadar sST2 sebagai penanda fibrosis jantung pada ketiga kelompok subjek penelitian, dengan kadar sST2 lebih tinggi pada subjek dengan penyintas COVID-19 disertai komorbiditas kardiovaskular. Terdapat hubungan PaO2 dan nilai CT saat admisi dengan kadar sST2.

---

Background : Recent findings showed that symptoms associated with COVID-19 infection may persist up to 90 days even after the acute disease period has passed. This condition is now termed as post COVID-19 syndrome. Several pathophysiologic mechanisms of this event had been proposed, all of which still needed further elaboration. One of the proposed mechanisms involves fibrotic processes in several organs, especially heart and the lungs. SST2 has been suggested as a novel biomarker for cardiac fibrosis. However data are still needed to further elucidate the factors which are associated with the incidence of fibrosis post COVID-19 infection. Furthermore, data regarding sST2 levels in patients with cardiovascular comorbidities and in healthy subjects are still limited.

Objective : Knowing the differences on sST2 levels between subjects with cardiovascular comorbidities 12 weeks post COVID-19 infection, those without history of COVID-19 but with cardiovascular comorbidities, and healthy population, as well as knowing its relationship with admission factors.

Methods : This study is a cross-sectional observational study on patients 3 months after COVID-19 infection presented with cardiovascular comorbidities. Age and sex-matched control groups were used as comparison. The results were compared with a group without history of COVID-19 and healthy populations. Relationship between admission factors was assessed using multivariate analysis

Results : 162 subjects completed the study series, consisting of 100 subjects with COVID-19 survivors with cardiovascular comorbidities (case group), 31 subjects with cardiovascular comorbidities without COVID-19 (control group 1), and 31 healthy subjects without a history of COVID-19 and cardiovascular comorbidities (control group 2). All three groups had similar characteristics. There was a significant difference in the mean sST2 value between the case groups compared to control 1 and control 2 (2786 ± 73 vs 2666 ± 162 pg/l, p < 0.001 and 2786 ± 73 vs 2517.15 ± 321 pg/l, p < 0.001 respectively), and control 1 compared to control 2 (2666 ± 162 pg/l vs 2517.15 ± 321 pg/l, p < 0.001). Multivariate analysis revealed PaO2 (p < 0.001 and CT values (p = 0.04) as admission factor associated with increased sST2 3 months after initial COVID-19 infection.

Conclusion : SST2 levels were found to be significantly different between the three groups, with the highest level on the case group (subjects with history of COVID-19 and cardiovascular comorbidities). Factors upon admissions which include Arterial oxygen partial pressure (PaO2) (p < 0.001) and CT value (p = 0.04) were found to be associated with increased sST2 levels."

"ABSTRAK Latar belakang: disglikemia adalah keadaan intoleransi glukosa berupa peningkatan kadar gula darah yang berhubungan dengan risiko penyakit kardiovaskular. Seiring dengan waktu, pada akhirnya diabetes akan menimbulkan kerusakan pada target organ, salah satu yang penting adalah pada sistem organ kardiovaskular, dapat berupa penyakit jantung koroner, kardiomiopati diabetes, penyakit serebrovaskuler, dan penyakit arteri perifer. Diabetes juga meningkatkan risiko terjadinya gagal jantung. Pada kardiomiopati diabetes, proses fibrosis yang masih reversibel sudah mulai terjadi bahkan ketika penderita masih asimtomatik. Pemeriksaan baku emas untuk mendeteksi terjadinya fibrosis miokard secara dini adalah pemeriksaan histopatologi jaringan miokardium melalui biopsi. Akan tetapi pemeriksaan ini sangat invasif dan tidak nyaman bagi subjek. Pemeriksaan yang kemudian berkembang adalah pencitraan menggunakan Cardiac Magnetic Resonance Imaging (CMRI). Akan tetapi pemeriksaan ini cukup mahal, dan tidak tersedia pada semua fasilitas kesehatan. Sementara itu, ST2 adalah penanda enzim jantung yang menggambarkan derajat proses fibrosis yang sedang terjadi pada miokard, terutama pada keadaan gagal jantung. Pemeriksaan menggunakan penanda enzim dapat menjadi alternatif dengan keuntungan lebih murah, dapat terjangkau luas dan mudah tersedia. Tujuan: Mengetahui hubungan antara kadar ST2 serum dengan fibrosis miokard interstisial pada penderita disglikemia. Metode: Pasien disglikemia yang lolos kriteria eksklusi berupa komorbid kardiovaskular akan menjalani pemeriksaan kadar ST2 serum dan T1 relaxation time menggunakan Cardiac MRI. Selanjutnya dilakukan analisis hubungan antara kadar ST2 serum dan T1 relaxation time. Hasil penelitian: Sebanyak 34 pasien diikutsertakan ke dalam penelitian ini. Didapatkan kisaran nilai kadar ST2 serum antara 12.40-53.22 ng/dL (median 19.95 ng/dL). Rerata nilai T1 relaxation time didapatkan sebesar 443.39 ± 113.35 ms. Terdapat korelasi bermakna antara kadar ST2 serum dengan fibrosis diffuse miokardium (Spearman correlation r = -0,547, p < 0.01). Pada analisa multivariat hubungan antara kadar ST2 serum dan T1 relaxation time tidak dipengaruhi oleh faktor perancu yang telah ditetapkan (r = -0,44, p = 0,033). Kesimpulan: Hasil penelitian ini menunjukkan kadar ST2 serum berkolerasi dengan fibrosis diffuse miokardium pada populasi disglikemia.ABSTRACT Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population.;Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population.;Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population.;Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population."